ConjuGon gets green light for drug trials

MADISON – A new investigatory drug by ConjuGon Inc. has completed regulatory review by the U.S. Food and Drug Administration. The application, used to prevent catheter-associated urinary tract infections, is now cleared to begin clinical trials. The drug, C-1205, is the company's lead product.

"Based on results from several previous studies, we have high hopes that C-1205 will help prevent bladder and other urinary tract infections," according to ConjuGon Chief Operating Officer Steve Watt.

Watt stated that patients who are catheterized, such as those with spinal cord injuries or the disabled elderly, will normally experience several urinary tract infections each year. "With this product, our expectation is that the number of urinary tract infections will be greatly reduced, treatment costs will be lowered, and patients' quality of life will be increased," he said.

The drug uses bacterial interference technology to inhibit bladder infections in spinal cord injury patients and
others with indwelling catheters. The active ingredient in the product has been previously tested in people for the prevention of urinary tract infections, and has been shown to be safe and effective.

ConjuGon is a clinical-stage biopharmaceutical company developing antibacterial technologies using harmless bacteria as drugs.

• Boston orthopedic technology firm courts Wisconsin investors for possible move
• ConjuGon secures $2.4 million in '09 defense dollars
• ConjuGon to receive $1.2 million in defense dollars